508 related articles for article (PubMed ID: 11261828)
1. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
2. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Cummings SR; Eckert S; Krueger KA; Grady D; Powles TJ; Cauley JA; Norton L; Nickelsen T; Bjarnason NH; Morrow M; Lippman ME; Black D; Glusman JE; Costa A; Jordan VC
JAMA; 1999 Jun; 281(23):2189-97. PubMed ID: 10376571
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
4. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
5. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
6. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
7. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
9. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
[TBL] [Abstract][Full Text] [Related]
10. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
Sporn MB; Dowsett SA; Mershon J; Bryant HU
Clin Ther; 2004 Jun; 26(6):830-40. PubMed ID: 15262454
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
[TBL] [Abstract][Full Text] [Related]
13. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
16. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
17. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
Ko SS; Jordan VC
Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
[TBL] [Abstract][Full Text] [Related]
19. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
Cohen FJ; Lu Y
Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
[TBL] [Abstract][Full Text] [Related]
20. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
Vogel VG
Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]